Grace Therapeutics, Inc. Payments of Debt Restructuring Costs
Grace Therapeutics, Inc. (GRCE) reported Payments of Debt Restructuring Costs of $1.21 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2023-08-11
- Grace Therapeutics, Inc. payments of debt restructuring costs for the quarter ending 2023-06-30 was $1.21M.
| Period end | Payments of Debt Restructuring Costs 3 month |
|---|---|
| 2023-06-30 | $1.21M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |